Patterns of Consultation and Treatment of Patients with Hepatocellular Carcinoma Presenting to a Large Academic Medical Center in the US

被引:18
作者
Stacy, Sylvie [1 ]
Hyder, Omar [1 ]
Cosgrove, David [2 ]
Herman, Joseph M. [3 ]
Kamel, Ihab [4 ]
Geschwind, Jean-Francois H. [5 ]
Gurakar, Ahmet [6 ]
Anders, Robert [7 ]
Cameron, Andrew [1 ]
Pawlik, Timothy M. [1 ,8 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Med Oncol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD USA
[4] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, Dept Intervent Radiol, Baltimore, MD USA
[6] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[7] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[8] Johns Hopkins Univ Hosp, Div Surg Oncol, Dept Surg, Baltimore, MD 21287 USA
关键词
Hepatocellular; Carcinoma; Referral patterns; Consultation; REFERRAL PATTERNS; UNITED-STATES; COLON-CANCER; POPULATION; DISPARITIES; MORTALITY; OUTCOMES; THERAPY; CARE;
D O I
10.1007/s11605-013-2253-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Management of hepatocellular carcinoma (HCC) often involves many subspecialist providers, as well as a broad range of treatment options. This study sought to evaluate referral and treatment patterns among patients with HCC at a large academic medical center. Data from our cancer registry between 2003-2011 were abstracted on 394 patients who were primarily diagnosed/treated for HCC at Johns Hopkins Hospital (JHH); data on patients who were diagnosed/treated with HCC elsewhere and who received secondary treatment at JHH (n = 391) were also abstracted for comparison purposes. Among the main cohort, the most common specialties to be consulted were surgery (n = 225, 57.1 %), gastroenterology (n = 225, 57.1 %), and interventional radiologist (n = 206, 52.3 %), while only 96 (24.4 %) were referred to medical oncology. Factors associated with surgical consultation included younger age (odds ratio (OR) 3.35, 95 % CI 1.62-6.92), tumor size < 5 cm (OR 1.82, 1.09-3.02), and unilobar disease (OR 2.94, 1.31-6.59) (all P < 0.05). Patients initially diagnosed/treated elsewhere had larger tumors (4 vs. 6 cm), bilateral disease (19.2 vs. 26.8 %), and were more likely to be seen by interventional radiology (all P < 0.05) Most patients were seen by surgeons, gastroenterologists, or interventional radiologists, with only a minority being seen by medical oncologists. Referral patterns depended on patient-level factors, as well as extent of disease.
引用
收藏
页码:1600 / 1608
页数:9
相关论文
共 31 条
  • [1] Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
    Altekruse, Sean F.
    McGlynn, Katherine A.
    Reichman, Marsha E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1485 - 1491
  • [2] Andaya AA, 2013, CANC EPIDEM BIOMAR
  • [3] [Anonymous], SEER STAT DAT INC SE
  • [4] [Anonymous], 2012, NCCN Clinical Practice Guidelines in Oncology: Breast Cancer
  • [5] Prognostic prediction and treatment strategy in hepatocellular carcinoma
    Bruix, J
    Llovet, JM
    [J]. HEPATOLOGY, 2002, 35 (03) : 519 - 524
  • [6] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [7] The American Heart Association's Recommendations for Expanding the Applications of Existing and Future Clinical Registries A Policy Statement From the American Heart Association
    Bufalino, Vincent J.
    Masoudi, Frederick A.
    Stranne, Steven K.
    Horton, Katie
    Albert, Nancy M.
    Beam, Craig
    Bonow, Robert O.
    Davenport, Roger L.
    Girgus, Meighan
    Fonarow, Gregg C.
    Krumholz, Harlan M.
    Legnini, Mark W.
    Lewis, William R.
    Nichol, Graham
    Peterson, Eric D.
    Rosamond, Wayne
    Rumsfeld, John S.
    Schwamm, Lee H.
    Shahian, David M.
    Spertus, John A.
    Woodard, Pamela K.
    Yancy, Clyde W.
    [J]. CIRCULATION, 2011, 123 (19) : 2167 - 2179
  • [8] Cance WG, 2000, CANCER, V88, P912, DOI 10.1002/(SICI)1097-0142(20000215)88:4<912::AID-CNCR23>3.0.CO
  • [9] 2-T
  • [10] Commission on Cancer, 2012, FAC ONC REG DAT STAN